Genvor (GNVR)

Genvor (OTCQB: $GNVR ) Appoints Donald Kalkofen as CFO to Support Dual-Market Growth Across Agriculture and Human Health Genvor Inc. (OTCQB: GNVR) announced the appointment of Don Kalkofen as Chief Financial Officer. Mr. Kalkofen will lead Genvor’s financial strategy as the company advances its dual-market commercialization plans across agriculture and human health. Genvor, Inc. is a B2i Digital Featured Company. Learn more at https://b2idigital.com/genvor. Mr. Kalkofen brings more than 20 years of public-company finance leadership experience across biotechnology, financial services, and technology, with a track record of guiding companies through initial public offerings and complex capital markets transactions. • Most recently served as CFO of Alpha Cognition, where he helped lead preparations for the company’s NASDAQ listing and build investor relations and audit infrastructure • Previously served as CFO of Protagonist Therapeutics, supporting SOX 404(b) implementation during a period of growth • Held senior finance roles at Symantec and West Coast Bancorp, helping take the bank public on NASDAQ and grow assets from $90 million to $1.5 billion • Certified Public Accountant (inactive) with a Bachelor of Arts in Accounting from Washington State University Chad Pawlak, Sr., Chief Executive Officer of Genvor, commented: “Don’s track record of guiding biotechnology companies through transformational growth makes him the ideal financial leader for Genvor at this stage of our development. His deep public company experience combined with his command of complex capital markets and partnership transactions positions him to support the structuring of future joint development agreements across both our agricultural and human health and wellness platforms.” See the press release at https://genvor.com/press-releases/post?storyId=7340692620742974 Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Genvor, Inc. (OTCQB: GNVR) is a biotechnology company harnessing AI to generate novel peptides that deliver high-performance solutions across agriculture and human health. Powered by its proprietary BioCypher platform and patented peptides, Genvor is developing and intends to commercialize biological actives for crop protection and plant health alongside consumer-focused peptide solutions for recovery, performance, anti-aging, and daily wellness. Through its technology platforms and future partnerships, Genvor intends to advance a new era of natural, science-based innovation. Genvor is led by Chief Executive Officer Chad Pawlak, Sr. and Chief Financial Officer Don Kalkofen, with co-founders Dr. Jesse Jaynes and Dr. Clayton Yates bringing decades of peptide research expertise. Learn more at www.genvor.com and about other B2i Digital Featured Companies at https://b2idigital.com/featured-companies. See the complete Disclosure at https://b2idigital.com/disclaimer.

Genvor Inc. (OTCQB: $GNVR ) Chief Executive Officer Chad Pawlak, Sr. recently presented at the Second Annual Centri Capital Conference at Nasdaq MarketSite, hosted by Centri Business Consulting. In this clip, he announces the company's first commercial licensing MOU. Genvor is a B2i Digital Featured Company (https://b2idigital.com/genvor-incorporated-1) that designs and licenses proprietary peptide sequences for agriculture and human health. For more information, visit https://www.genvor.com and follow Genvor on LinkedIn. "This morning we had a press release that went out and we signed our first MOU on a commercial pathway for five peptides with a company called CanLabs. They've come to us and said, we want you to design up to 20 sequences that will be unique to us in this MedSpa physician space," Pawlak announced, marking Genvor's first commercial licensing deal. The economics and structure of the Canlab International MOU and the Platform Licensing Model arrangement: • The financial structure is $1 million per sequence or 11% royalty on net sales, whichever is higher on an annualized basis, for CanLabs to maintain exclusivity on each sequence. • Initial scope covers five sequences with a path to 20, representing a potential annual sequencing opportunity of up to $20 million annual sequencing opportunity before royalties on product sales. • The MedSpa and physician channel is a commercially active market today, which allows Genvor to generate revenue while the agricultural business continues to develop through longer regulatory and commercialization cycles. • The deal validates the platform’s commercial flexibility: in agriculture, Genvor’s licensing-first model puts validated peptide technology into the hands of Tier-1 partners, while in human health and wellness, the same platform supports both licensing arrangements like Canlab International and direct-to-consumer programs in development. Watch the full presentation, courtesy of Centri Business Consulting: https://youtu.be/BSYxwOnxZmM Genvor is led by Chief Executive Officer Chad Pawlak, Sr., with co-founders Dr. Jesse Jaynes and Dr. Clayton Yates, whose peptide sequence design work dates back to the 1970s. George Stavrides serves as Executive Vice President of Business Development and Commercialization. For additional details, please visit the Investors section of Genvor's website at: https://www.genvor.com. For investor inquiries, contact [email protected]. Content shared here is for general information only and is not an offer to buy or sell any security. Any securities-related activities by our personnel are conducted solely through an appropriately registered broker-dealer, separate from services provided by B2i Digital.

Genvor Inc. (OTCQB: $GNVR ) Chief Executive Officer Chad Pawlak, Sr. recently presented at the Second Annual Centri Capital Conference at Nasdaq MarketSite, hosted by Centri Business Consulting. In this clip, he describes the agricultural validation work behind Genvor's peptide platform. Genvor is a B2i Digital Featured Company (https://b2idigital.com/genvor-incorporated-1) that designs and licenses proprietary peptide sequences for agriculture and human health. For more information, visit https://www.genvor.com and follow Genvor on LinkedIn. "We have a number of different peptides that are currently proven to be efficacious with 12 different diseases where we can show 90 plus percent immunity at the seed genetic level. In other words, we can plant a corn seed and we know with 90 plus percent accuracy that those plants will not grow with that disease. Nobody's done that with a peptide," Pawlak said, highlighting what the USDA collaboration has produced. More than seven years of federal-agency collaboration and the industry validation that has come with it: • The original USDA aflatoxin program funded 20 companies. Nineteen of them have exited. Genvor is the one still standing, with the working technology to show for it. • The work has produced three peer-reviewed papers and multiple patents, providing both scientific credibility and defensible intellectual property. • Genvor's teaming agreement with Tuskegee University connects the company to foundational academic peptide research. Co-founder Dr. Clayton Yates now holds an endowed professorship at Johns Hopkins. • The agricultural opportunity has received positive signaling from the four dominant agricultural majors, and ex-Syngenta executive George Stavrides, who evaluated more than 500 active ingredients at Syngenta, has joined Genvor as EVP Business Development and Commercialization. Watch the full presentation, courtesy of Centri Business Consulting: https://youtu.be/BSYxwOnxZmM Genvor is led by Chief Executive Officer Chad Pawlak, Sr., with co-founders Dr. Jesse Jaynes and Dr. Clayton Yates, whose peptide sequence design work dates back to the 1970s. George Stavrides serves as Executive Vice President of Business Development and Commercialization. For additional details, please visit the Investors section of Genvor's website at: https://www.genvor.com. For investor inquiries, contact [email protected]. Content shared here is for general information only and is not an offer to buy or sell any security. Any securities-related activities by our personnel are conducted solely through an appropriately registered broker-dealer, separate from services provided by B2i Digital.

Genvor, Inc. (OTCQB: $GNVR ) Chief Executive Officer Chad Pawlak, Sr. recently presented at the Second Annual Centri Capital Conference at Nasdaq MarketSite, hosted by Centri Business Consulting. In this clip, he places Genvor's peptide platform in the context of the broader evolution of biological products. Genvor is a B2i Digital Featured Company (https://b2idigital.com/genvor-incorporated-1) that designs and licenses proprietary peptide sequences for agriculture and human health. For more information, visit https://www.genvor.com and follow Genvor on LinkedIn. Watch the clip here: https://youtube.com/shorts/TzxBMulWDqw "My background is two previous biological spaces for agriculture. First generation of biologicals would be plant extracts, seaweeds, those kinds of biostimulants. Second generation would include microbes. And now people are referring to this third generation of biologicals, which are peptides, proteins and enzymes," Pawlak explained, describing the category evolution that Genvor is positioned to lead. The leap from second-generation microbes to third-generation peptides is not incremental: • Each successive generation of biologicals has brought more precision and more targeted efficacy than the one before. Peptides sit at the leading edge of that progression. • Peptide sequence design is mathematically intractable without modern computational tools. A 15-amino-acid peptide drawn from 20 building blocks would take 200 years to enumerate manually. • Genvor's BioCypher platform builds on more than four decades of peptide sequence design work by co-founders Dr. Jesse Jaynes and Dr. Clayton Yates, feeding that domain knowledge into a machine learning system that can generate peptide candidate sequences at scale. • The licensing-first business model in agriculture functions like an architectural firm: Genvor designs sequences, and partners handle regulatory, manufacturing, distribution, and marketing. The model is capital-efficient and scales across sectors. Watch the full presentation, courtesy of Centri Business Consulting: https://youtu.be/BSYxwOnxZmM Genvor is led by Chief Executive Officer Chad Pawlak, Sr., with co-founders Dr. Jesse Jaynes and Dr. Clayton Yates, whose peptide sequence design work dates back to the 1970s. George Stavrides serves as Executive Vice President of Business Development and Commercialization. For additional details, please visit the Investors section of Genvor's website at: https://www.genvor.com. For investor inquiries, contact [email protected]. Content shared here is for general information only and is not an offer to buy or sell any security. Any securities-related activities by our personnel are conducted solely through an appropriately registered broker-dealer, separate from services provided by B2i Digital.

$GNVR 💪🧬

Genvor, Inc. (OTCQB: $GNVR ) announced the execution of a non-binding Memorandum of Understanding with Canlab International™, a peptide manufacturing company with a broad clinical distribution network, establishing a framework for the potential development, manufacturing, and commercialization of novel natural peptide candidates. Genvor, Inc. is a B2i Digital Featured Company. Learn more at https://b2idigital.com/genvor-incorporated-1. The MOU targets large and growing end markets including weight management, anti-aging and longevity, tissue repair and regeneration, hair restoration, and hormonal optimization. The parties intend to initiate development of approximately five peptide candidates in 2026, with a roadmap to expand the pipeline to twenty or more candidates subject to validation and commercial readiness. The collaboration pairs Genvor’s BioCypher™ peptide design platform and IP strategy with Canlab’s manufacturing capabilities and established network of more than 5,000 physicians and 500 medical spa operators. The agreement contemplates preferred manufacturing and distribution rights for Canlab within defined channels, subject to performance-based conditions and future definitive agreements. For each peptide target category, Genvor anticipates potential economic participation structures that may include target annual payments of approximately $1 million or royalty-based participation of approximately 11% on net sales, subject to future definitive agreements. Chad Pawlak, Sr., Chief Executive Officer of Genvor, said: “Our collaboration with Canlab marks a significant step forward in demonstrating the commercial applicability of our BioCypher™ platform. We believe this framework has the potential to translate our peptide innovation into scalable, revenue-generating products across multiple high-demand categories. Importantly, this is our first structured commercial agreement of this kind and reinforces our strategy of aligning platform-driven discovery with established manufacturing and distribution partners.” Gary Gaul, ND, Founder and CEO of Canlab International™, said: “By combining Genvor’s proprietary sequencing and design capabilities with Canlab’s expertise in high-purity peptide synthesis and process optimization, we are establishing a foundation for the disciplined development and potential commercialization of differentiated compounds.” Read the full press release: https://genvor.com/press-releases/post?webmasterId=131326&qmodStoryID=6359304231179147 Genvor, Inc. is led by Chief Executive Officer Chad Pawlak, Sr., with co-founders Dr. Jesse Jaynes and Dr. Clayton Yates bringing years of peptide research expertise. To learn more about Genvor, Inc., visit https://www.genvor.com. For investor inquiries, contact [email protected].

At NIBA's 152nd Investment Conference in Fort Lauderdale on March 12, 2026, Genvor, Inc. (OTCQB: $GNVR ) CEO Chad Pawlak, Sr. explained how a decades-old algorithm puts the company in a position to compete with major ag-chem players -- and to expand well beyond agriculture. Genvor Inc. is a B2i Digital Featured Company. Learn more at https://b2idigital.com/genvor-incorporated-1. "The way we compete with companies like Bayer and Syngenta and BASF -- and on the health and wellness side now that we've entered into that sector -- is we're saving hundreds of years of R&D with these companies based on the algorithm that Jesse designed in the 1980s, before Bill Gates was anybody, before Excel was anything, and before any of us were in love with machine learning and AI." Genvor's platform and strategic position: Current focus on two markets: agricultural biologicals and human health and wellness Platform is market-agnostic; the same peptide design capability can be applied across industries Assets include issued patents, a USDA-ARS research partnership, and commercially ready products Two open Reg D offerings currently available for qualified investors Read the press release: https://finance.yahoo.com/news/genvor-inc-presenting-nibas-152nd-130000396.html Genvor is led by CEO Chad Pawlak, Sr. with co-founders Dr. Jesse Jaynes and Dr. Clayton Yates bringing decades of peptide research expertise. To learn more about Genvor Inc., visit https://www.genvor.com. For investor inquiries, contact [email protected]. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security.

Genvor, Inc. (OTCQB: $GNVR) announced that the Company will present at the Centri Capital Conference on Tuesday, April 14, at Nasdaq in New York City. CEO Chad Pawlak, Sr. will discuss the Company's recent performance and future growth plans. Genvor, Inc. is a B2i Digital Featured Company. Learn more at https://b2idigital.com/genvor-incorporated-1. Companies and investors interested in attending or learning more can visit www.CentriConsulting.com/capital-conference. Read the full press release: https://www.genvor.com/press-releases/post?storyId=5086495074924124 Genvor is a biotechnology company harnessing AI to generate novel peptides that deliver high-performance solutions across agriculture and human health and wellness. Genvor's proprietary BioCypher platform designs peptides that enhance crop performance, reduce chemical inputs, and support human recovery and wellness. Through strategic partnerships and a dual-market commercialization model, Genvor is advancing peptide science from field to finish line. For more information, visit www.genvor.com. Genvor, Inc. is led by Chief Executive Officer Chad Pawlak, Sr., with co-founders Dr. Jesse Jaynes and Dr. Clayton Yates. To learn more about Genvor, Inc., visit https://www.genvor.com. For investor inquiries, contact Carly Scaduto at [email protected]. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security.

At NIBA's 152nd Investment Conference in Fort Lauderdale on March 12, 2026, Genvor, Inc. (OTCQB: $GNVR ) CEO Chad Pawlak used a memorable analogy to explain what makes Genvor's peptide design platform different from anything else in the market. Genvor Inc. is a B2i Digital Featured Company. Learn more at https://b2idigital.com/genvor-incorporated-1. "God gave us 20 amino acids. That's it. So when it comes to designing a peptide, you have 20 ingredients... If I sent you to that grocery store blindfolded and said, 'Go pick seven ingredients to make chocolate chip cookies,' God only knows what you'd bring back. But now if I did that with peptides and said, 'Design a 15 amino acid peptide -- come back with all your optionality'... any thoughts on how long that would take? 200 years working 24 hours a day, seven days a week. That's the secret sauce we have at Genvor." What makes Genvor's BioCypher platform different: • Built on an algorithm developed by co-founder Dr. Jesse Jaynes beginning in the early 1980s • Jaynes phenotyped all 20 amino acids, building a design language for peptides before machine learning existed • The platform can sequence peptides at a speed and confidence level no competitor can replicate • Result: hundreds of thousands of candidates screened down to the most efficacious, lowest-cost leads Watch the clip: https://youtube.com/shorts/-NECSrsCeoQ?feature=share Read the press release: https://finance.yahoo.com/news/genvor-inc-presenting-nibas-152nd-130000396.html Genvor is led by CEO Chad Pawlak, with co-founders Dr. Jesse Jaynes and Dr. Clayton Yates bringing decades of peptide research expertise. To learn more about Genvor Inc., visit https://www.genvor.com. For investor inquiries, contact [email protected]. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security.

$GNVR $GNVR $AI